SANTOSOLVE

SantoSolve is developing topical analgesic products based on strontium as the active agent. The Company's lead product, 2PX, is a low viscosity fluid administered topically at the site of pain. Preclinical and clinical studies have shown the product to have an excellent safety profile and strong analgesic effects in both nociceptive and neuropathic pain conditions.

In 2009 the Company advanced 2PX into pivotal Phase III trials in both osteoarthritis of the knee (recruitment completed end 2009) and in chronic post-amputation pain (recruitment is ongoing). Both trials are expected to report results during 2010, and planning for confirmatory phase III trials are underway.

The Company expects to be able to file an NDA during 2012.

Pain is the most common reason patients seek medical care, accounting for 50% of all physician office visits in the United States and is impacting the daily lifes of more than 70 million Americans very year.

Safe and effective treatment of pain remains a key challenge facing the patient and health care professionals everywhere. Currently available pain drugs are linked to substantial risk of adverse effects. NSAID use alone is the direct cause of more than 100.000 hospitalizations and 30.000 deaths annually in the US.

Our ambition is to be able to offer pain sufferers a new and effective pain medication, without the serious adverse effects and health risks associated with existing pain drugs.

Latest news

Novel active substance

Calcium is required as a catalyst for a number of biological reactions. Strontium is chemically very similar to calcium, and can in most biological reactions substitute for calcium. However, strontium has an antagonistic effect on certain calcium-driven reactions involved in pain and inflammatory processes, motivating the use of strontium therapeutically to inhibit key biological pathways involved in pain signalling.

General links